Text Size

Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia

This study has been completed.
Sponsor:
Collaborator:
Universidad Autonoma del Estado de Mexico
Information provided by (Responsible Party):
Hugo Mendieta Zeron, Materno-Perinatal Hospital of the State of Mexico
ClinicalTrials.gov Identifier:
NCT01649167
First received: July 17, 2012
Last updated: July 24, 2012
Last verified: July 2012
History of Changes
  Purpose

Background: Obesity in pregnancy is increasing and is a risk factor for metabolic pathology such as preeclampsia. Leptin is an adipokine which has a direct relationship to obesity.

Aim: to measure leptin in lean, obese and diabetic pregnant women at three months intervals throughout their pregnancies.

Methods: Pregnant women were recruited in the 1st trimester of pregnancy, and three groups were formed: a) with pregestational Body Mass Index (BMI) less than 25 kg/m2, b) BMI higher than 25 kg/m2 and c) with Gestational Diabetes Mellitus (GDM). Serum levels of leptin were measured with radioimmunoassay (RIA) technique.


Condition
High-Risk Pregnancy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia

Resource links provided by NLM:

MedlinePlus related topics: Diabetes Obesity
U.S. FDA Resources

Further study details as provided by Materno-Perinatal Hospital of the State of Mexico:

Biospecimen Retention:   Samples Without DNA

Serum


Enrollment: 55
Study Start Date: February 2009
Study Completion Date: November 2010
Groups/Cohorts
Overweight/obesity
Pregnant women with overweight/obesity
gestational diabetes
Pregnant women with gestational diabetes
normal weight
Pregnant women with normal weight

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   16 Years to 46 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Women who had received medical attention during pregnancy at the HMPMP in Toluca, Mexico.

Criteria

Inclusion Criteria:

  • Women in the first trimester of pregnancy who sought medical attention at the HMPMP, between 16 and 46 years of age with a singleton gestation.

Exclusion Criteria:

  • A previously known chronic metabolic disease (diabetes, pregestational dyslipidemia, hypertension, collagen vascular diseases, inflammatory bowel disease and chronic inflammatory conditions, or corticosteroid use).
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01649167

Sponsors and Collaborators
Materno-Perinatal Hospital of the State of Mexico
Universidad Autonoma del Estado de Mexico
Investigators
Principal Investigator: Verónica Jackeline García Solorio, MSc Autonomous University of the State of Mexico
Study Chair: Hugo Mendieta Zerón, PhD Autonomous University of the State of Mexico
  More Information

No publications provided

Responsible Party: Hugo Mendieta Zeron, Researcher of the Medical Research Center (CICMED), Materno-Perinatal Hospital of the State of Mexico
ClinicalTrials.gov Identifier: NCT01649167     History of Changes
Other Study ID Numbers: MACSSD042010
Study First Received: July 17, 2012
Last Updated: July 24, 2012
Health Authority: Mexico: Secretaria de Salud

Keywords provided by Materno-Perinatal Hospital of the State of Mexico:
body mass index
gestational diabetes
leptin
obesity
pregnancy.

Additional relevant MeSH terms:
Pre-Eclampsia
Hypertension, Pregnancy-Induced
Pregnancy Complications

ClinicalTrials.gov processed this record on June 18, 2013